Tectonic Therapeutic to present positive phase 1a results of TX45, …
1 day ago · Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced detailed results from the phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin ...
EnteroBiotix reports positive results from phase 1b IMPuLCE study …
1 day ago · EnteroBiotix’s first-in-human study of EBX-102 was a randomised, double-blind, placebo-controlled Ph1b study of adult participants with stable liver cirrhosis. It was designed to evaluate the safety, tolerability, and translational biomarker effects of two different doses of EBX-102. The study was conducted across ten sites in the United Kingdom.
Paratek Pharma announces positive top-line data from phase 2b …
2 days ago · Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for serious diseases, announced top-line results from its phase 2b study of oral omadacycline in adult patients with Nontuberculous ...
Neurizon Therapeutics receives positive opinion on orphan …
1 day ago · Neurizon Therapeutics Limited (Neurizon), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, announced it has received notice of a positive opinion from the European Medicines Agency (EMA) for Orphan Medicinal Product Designation (OMPD) following its application ...
Harbour BioMed submits IND application for HBM9378/SKB378 to …
2 days ago · Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announced the submission of an IND application to the Centre for Drug Evaluation of the National Medical Products ...
STEERLife & Callidus Research Laboratories forge strategic …
1 day ago · STEERLife, a pioneer in pharmaceutical development technologies, and Callidus Research Laboratories, a formulation development services company with a wealth of experience in comprehensive pharmaceutical drug development, have forged a strategic partnership to accelerate drug development for global ...
Novo Nordisk announces positive results from phase 3 ESSENCE …
Nov 5, 2024 · Novo Nordisk, a leading global healthcare company, announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 ...
Lilly's mirikizumab is first and only IL23p19 antagonist to report …
Oct 29, 2024 · Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both UC & Crohn's disease
Dizal gets China NMPA breakthrough therapy designation for ...
Oct 15, 2024 · Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for ...
TopNews - Pharmabiz.com
6 days ago · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing.